The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

Catherine E. Steding, Sung tse Wu, Yanping Zhang, Meei Huey Jeng, Bennett D. Elzey, Chinghai Kao

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Myeloid-derived suppressor cells (MDSC) are important to the tumour microenvironment as they actively suppress the immune system and promote tumour progression and metastasis. These cells block T-cell activation in the tumour microenvironment, preventing anti-tumour immune activity. The ability of a treatment to alter the suppressive function of these cells and promote an immune response is essential to enhancing overall therapeutic efficacy. Interleukin-12 (IL-12) has the potential not only to promote anti-tumour immune responses but also to block the activity of cells capable of immune suppression. This paper identifies a novel role for IL-12 as a modulator of MDSC activity, with implications for IL-12 as a therapeutic agent. Treatment with IL-12 was found to alter the suppressive function of MDSC by fundamentally altering the cells. Interleukin-12-treated MDSC exhibited up-regulation of surface markers indicative of mature cells as well as decreases in nitric oxide synthase and interferon-γ mRNA both in vitro and in vivo. Treatment with IL-12 was also found to have significant therapeutic benefit by decreasing the percentage of MDSC in the tumour microenvironment and increasing the percentage of active CD8+ T cells. Treatment with IL-12 resulted in an increase in overall survival accompanied by a reduction in metastasis. The findings in this paper identify IL-12 as a modulator of immune suppression with significant potential as a therapeutic agent for metastatic breast cancer.

Original languageEnglish
Pages (from-to)221-238
Number of pages18
JournalImmunology
Volume133
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

Interleukin-12
Neoplasm Metastasis
Tumor Microenvironment
T-Lymphocytes
Neoplasms
Myeloid-Derived Suppressor Cells
Therapeutics
Nitric Oxide Synthase
Interferons
Immune System
Up-Regulation
Breast Neoplasms
Messenger RNA

Keywords

  • Gr-1/CD11b
  • IL-12
  • Immune suppressor
  • Macrophage
  • MDSC

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. / Steding, Catherine E.; Wu, Sung tse; Zhang, Yanping; Jeng, Meei Huey; Elzey, Bennett D.; Kao, Chinghai.

In: Immunology, Vol. 133, No. 2, 06.2011, p. 221-238.

Research output: Contribution to journalArticle

Steding, Catherine E. ; Wu, Sung tse ; Zhang, Yanping ; Jeng, Meei Huey ; Elzey, Bennett D. ; Kao, Chinghai. / The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. In: Immunology. 2011 ; Vol. 133, No. 2. pp. 221-238.
@article{bc1c4bcd425a48b4b4c6eee3e60bc7d9,
title = "The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis",
abstract = "Myeloid-derived suppressor cells (MDSC) are important to the tumour microenvironment as they actively suppress the immune system and promote tumour progression and metastasis. These cells block T-cell activation in the tumour microenvironment, preventing anti-tumour immune activity. The ability of a treatment to alter the suppressive function of these cells and promote an immune response is essential to enhancing overall therapeutic efficacy. Interleukin-12 (IL-12) has the potential not only to promote anti-tumour immune responses but also to block the activity of cells capable of immune suppression. This paper identifies a novel role for IL-12 as a modulator of MDSC activity, with implications for IL-12 as a therapeutic agent. Treatment with IL-12 was found to alter the suppressive function of MDSC by fundamentally altering the cells. Interleukin-12-treated MDSC exhibited up-regulation of surface markers indicative of mature cells as well as decreases in nitric oxide synthase and interferon-γ mRNA both in vitro and in vivo. Treatment with IL-12 was also found to have significant therapeutic benefit by decreasing the percentage of MDSC in the tumour microenvironment and increasing the percentage of active CD8+ T cells. Treatment with IL-12 resulted in an increase in overall survival accompanied by a reduction in metastasis. The findings in this paper identify IL-12 as a modulator of immune suppression with significant potential as a therapeutic agent for metastatic breast cancer.",
keywords = "Gr-1/CD11b, IL-12, Immune suppressor, Macrophage, MDSC",
author = "Steding, {Catherine E.} and Wu, {Sung tse} and Yanping Zhang and Jeng, {Meei Huey} and Elzey, {Bennett D.} and Chinghai Kao",
year = "2011",
month = "6",
doi = "10.1111/j.1365-2567.2011.03429.x",
language = "English",
volume = "133",
pages = "221--238",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

AU - Steding, Catherine E.

AU - Wu, Sung tse

AU - Zhang, Yanping

AU - Jeng, Meei Huey

AU - Elzey, Bennett D.

AU - Kao, Chinghai

PY - 2011/6

Y1 - 2011/6

N2 - Myeloid-derived suppressor cells (MDSC) are important to the tumour microenvironment as they actively suppress the immune system and promote tumour progression and metastasis. These cells block T-cell activation in the tumour microenvironment, preventing anti-tumour immune activity. The ability of a treatment to alter the suppressive function of these cells and promote an immune response is essential to enhancing overall therapeutic efficacy. Interleukin-12 (IL-12) has the potential not only to promote anti-tumour immune responses but also to block the activity of cells capable of immune suppression. This paper identifies a novel role for IL-12 as a modulator of MDSC activity, with implications for IL-12 as a therapeutic agent. Treatment with IL-12 was found to alter the suppressive function of MDSC by fundamentally altering the cells. Interleukin-12-treated MDSC exhibited up-regulation of surface markers indicative of mature cells as well as decreases in nitric oxide synthase and interferon-γ mRNA both in vitro and in vivo. Treatment with IL-12 was also found to have significant therapeutic benefit by decreasing the percentage of MDSC in the tumour microenvironment and increasing the percentage of active CD8+ T cells. Treatment with IL-12 resulted in an increase in overall survival accompanied by a reduction in metastasis. The findings in this paper identify IL-12 as a modulator of immune suppression with significant potential as a therapeutic agent for metastatic breast cancer.

AB - Myeloid-derived suppressor cells (MDSC) are important to the tumour microenvironment as they actively suppress the immune system and promote tumour progression and metastasis. These cells block T-cell activation in the tumour microenvironment, preventing anti-tumour immune activity. The ability of a treatment to alter the suppressive function of these cells and promote an immune response is essential to enhancing overall therapeutic efficacy. Interleukin-12 (IL-12) has the potential not only to promote anti-tumour immune responses but also to block the activity of cells capable of immune suppression. This paper identifies a novel role for IL-12 as a modulator of MDSC activity, with implications for IL-12 as a therapeutic agent. Treatment with IL-12 was found to alter the suppressive function of MDSC by fundamentally altering the cells. Interleukin-12-treated MDSC exhibited up-regulation of surface markers indicative of mature cells as well as decreases in nitric oxide synthase and interferon-γ mRNA both in vitro and in vivo. Treatment with IL-12 was also found to have significant therapeutic benefit by decreasing the percentage of MDSC in the tumour microenvironment and increasing the percentage of active CD8+ T cells. Treatment with IL-12 resulted in an increase in overall survival accompanied by a reduction in metastasis. The findings in this paper identify IL-12 as a modulator of immune suppression with significant potential as a therapeutic agent for metastatic breast cancer.

KW - Gr-1/CD11b

KW - IL-12

KW - Immune suppressor

KW - Macrophage

KW - MDSC

UR - http://www.scopus.com/inward/record.url?scp=79954987520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954987520&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2567.2011.03429.x

DO - 10.1111/j.1365-2567.2011.03429.x

M3 - Article

C2 - 21453419

AN - SCOPUS:79954987520

VL - 133

SP - 221

EP - 238

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 2

ER -